Literature DB >> 23039150

Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and its impact on overall survival. A single-institution experience in 190 patients: clinical article.

Tamara Ius1, Miriam Isola, Riccardo Budai, Giada Pauletto, Barbara Tomasino, Luciano Fadiga, Miran Skrap.   

Abstract

OBJECT: A growing number of published studies have recently demonstrated the role of resection in overall survival (OS) for patients with gliomas. In this retrospective study, the authors objectively investigated the role of the extent of resection (EOR) in OS in patients with low-grade gliomas (LGGs).
METHODS: Between 1998 and 2011, 190 patients underwent surgery for LGGs. All surgical procedures were conducted under corticosubcortical stimulation. The EOR was established by analyzing the pre- and postoperative volumes of the gliomas on T2-weighted MRI studies. The difference between the preoperative tumor volumes was also investigated by measuring the volumetric difference between the T2- and T1-weighted MRI images (ΔVT2T1) to evaluate how the diffusive tumor-growing pattern affected the EOR achieved.
RESULTS: The median preoperative tumor volume was 55 cm(3), and in almost half of the patients the EOR was greater than 90%. In this study, patients with an EOR of 90% or greater had an estimated 5-year OS rate of 93%, those with EOR between 70% and 89% had a 5-year OS rate of 84%, and those with EOR less than 70% had a 5-year OS rate of 41% (p < 0.001). New postoperative deficits were noted in 43.7% of cases, while permanent deficits occurred in 3.16% of cases. There were 41 deaths (21.6%), and the median follow-up was 4.7 years. A further volumetric analysis was also conducted to compare 2 different intraoperative protocols (Series 1 [intraoperative electrical stimulation alone] vs Series 2 [intraoperative stimulation plus overlap of functional MRI/fiber tracking diffusion tensor imaging data on a neuronavigation system]). Patients in Series 1 had a median EOR of 77%, while those in Series 2 had a median EOR of 90% (p = 0.0001). Multivariate analysis showed that OS is influenced not only by EOR (p = 0.001) but also by age (p = 0.003), histological subtype (p = 0.005), and the ΔVT2T1 value (p < 0.0001). Progression-free survival is similarly influenced by histological subtype (fibrillary astrocytoma, p = 0.003), EOR (p < 0.0001), and ΔVT2T1 value (p < 0.0001), as is malignant progression-free survival (p = 0.003, p < 0.0001, and p < 0.0001, respectively). Finally, the study shows that the higher the ΔVT2T1 value, the less extensive the currently possible resection, highlighting an apparent correlation between the ΔVT2T1 value itself and EOR (p < 0.0001).
CONCLUSIONS: The EOR and the ΔVT2T1 values are the strongest independent predictors in improving OS as well as in delaying tumor progression and malignant transformation. Furthermore, the ΔVT2T1 value may be useful as a predictive index for EOR. Finally, due to intraoperative corticosubcortical mapping and the overlap of functional data on the neuronavigation system, major resection is possible with an acceptable risk and a significant increase in expected OS.

Entities:  

Mesh:

Year:  2012        PMID: 23039150     DOI: 10.3171/2012.8.JNS12393

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  78 in total

1.  Polymalic acid chlorotoxin nanoconjugate for near-infrared fluorescence guided resection of glioblastoma multiforme.

Authors:  Rameshwar Patil; Anna Galstyan; Tao Sun; Ekaterina S Shatalova; Pramod Butte; Adam N Mamelak; Christine Carico; David S Kittle; Zachary B Grodzinski; Antonella Chiechi; Hui Ding; Keith L Black; Julia Y Ljubimova; Eggehard Holler
Journal:  Biomaterials       Date:  2019-03-23       Impact factor: 12.479

Review 2.  Awake surgery between art and science. Part I: clinical and operative settings.

Authors:  Andrea Talacchi; Barbara Santini; Francesca Casagrande; Franco Alessandrini; Giada Zoccatelli; Giovanna M Squintani
Journal:  Funct Neurol       Date:  2013 Jul-Sep

3.  Acquisition models in intraoperative positron surface imaging.

Authors:  Frédéric Monge; Dzhoshkun I Shakir; Florence Lejeune; Xavier Morandi; Nassir Navab; Pierre Jannin
Journal:  Int J Comput Assist Radiol Surg       Date:  2016-10-06       Impact factor: 2.924

Review 4.  IDH wild-type WHO grade II diffuse low-grade gliomas. A heterogeneous family with different outcomes. Systematic review and meta-analysis.

Authors:  Davide Tiziano Di Carlo; Hugues Duffau; Federico Cagnazzo; Nicola Benedetto; Riccardo Morganti; Paolo Perrini
Journal:  Neurosurg Rev       Date:  2018-06-26       Impact factor: 3.042

5.  Current Management of Adult Diffuse Infiltrative Low Grade Gliomas.

Authors:  Emilie Le Rhun; Sophie Taillibert; Marc C Chamberlain
Journal:  Curr Neurol Neurosci Rep       Date:  2016-02       Impact factor: 5.081

6.  On the use of fluorescein-based contrast agents as analogs to MRI-gadolinium agents for imaging brain tumors.

Authors:  Scott C Davis; Margaret R Folaron; Rendall R Strawbridge; Caroline Filan; Kimberley S Samkoe; David W Roberts
Journal:  Proc SPIE Int Soc Opt Eng       Date:  2019-03-07

Review 7.  'Low grade glioma': an update for radiologists.

Authors:  Jennifer Larsen; Steve B Wharton; Fiona McKevitt; Charles Romanowski; Caroline Bridgewater; Hesham Zaki; Nigel Hoggard
Journal:  Br J Radiol       Date:  2016-12-07       Impact factor: 3.039

8.  Patterns of care and treatment outcomes in older adults with low grade glioma: a 50-year experience.

Authors:  Ryan S Youland; David A Schomas; Paul D Brown; Ian F Parney; Nadia N I Laack
Journal:  J Neurooncol       Date:  2017-04-21       Impact factor: 4.130

Review 9.  Surgical strategy for insular glioma.

Authors:  Colin J Przybylowski; Shawn L Hervey-Jumper; Nader Sanai
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

Review 10.  Incidental diffuse low-grade gliomas: from early detection to preventive neuro-oncological surgery.

Authors:  Guilherme Lucas de Oliveira Lima; Marc Zanello; Emmanuel Mandonnet; Luc Taillandier; Johan Pallud; Hugues Duffau
Journal:  Neurosurg Rev       Date:  2015-11-27       Impact factor: 3.042

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.